Trial · NCT00430248
Adverse events177
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 177
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper Respiratory Tract Infections | Infections and infestations | Febuxostat 40 mg QD | 71 | 757 | |
| other | Upper Respiratory Tract Infections | Infections and infestations | Febuxostat 80 mg QD | 53 | 756 | |
| other | Upper Respiratory Tract Infections | Infections and infestations | Allopurinol 200 mg or 300 mg QD | 57 | 756 | |
| other | Liver Function Analyses | Investigations | Febuxostat 40 mg QD | 63 | 757 | |
| other | Liver Function Analyses | Investigations | Febuxostat 80 mg QD | 52 | 756 | |
| other | Liver Function Analyses | Investigations | Allopurinol 200 mg or 300 mg QD | 50 | 756 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Febuxostat 40 mg QD | 45 | 757 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Febuxostat 80 mg QD | 47 | 756 | |
| other | Diarrhoea (Excluding Infective) | Gastrointestinal disorders | Allopurinol 200 mg or 300 mg QD | 57 | 756 | |
| other | Musculoskeletal and Connective Tissues Signs and Symptoms NEC | Musculoskeletal and connective tissue disorders | Febuxostat 40 mg QD | 43 | 757 | |
| other | Musculoskeletal and Connective Tissues Signs and Symptoms NEC | Musculoskeletal and connective tissue disorders | Febuxostat 80 mg QD | 38 | 756 | |
| other | Musculoskeletal and Connective Tissues Signs and Symptoms NEC | Musculoskeletal and connective tissue disorders | Allopurinol 200 mg or 300 mg QD | 32 | 756 | |
| serious | Leukocytoses not elsewhere classified (NEC) | Blood and lymphatic system disorders | Febuxostat 40 mg QD | 0 | 757 | |
| serious | Leukocytoses not elsewhere classified (NEC) | Blood and lymphatic system disorders | Febuxostat 80 mg QD | 1 | 756 | |
| serious | Leukocytoses not elsewhere classified (NEC) | Blood and lymphatic system disorders | Allopurinol 200 mg or 300 mg QD | 0 | 756 | |
| serious | Thrombocytopenias | Blood and lymphatic system disorders | Febuxostat 40 mg QD | 0 | 757 | |
| serious | Thrombocytopenias | Blood and lymphatic system disorders | Febuxostat 80 mg QD | 1 | 756 | |
| serious | Thrombocytopenias | Blood and lymphatic system disorders | Allopurinol 200 mg or 300 mg QD | 0 | 756 | |
| serious | Cardiac Conduction Disorders | Cardiac disorders | Febuxostat 40 mg QD | 0 | 757 | |
| serious | Cardiac Conduction Disorders | Cardiac disorders | Febuxostat 80 mg QD | 2 | 756 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00430248/events